Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment
Use of Pradaxa® (Dabigatran Etexilate) for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Mild to Moderate Renal Impairment
Sponsor: Boehringer Ingelheim
Listed as NCT01721837, this observational or N/A phase trial focuses on Atrial Fibrillation and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 14 times since 2012, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Completed
-
Nov 2025 — Feb 2026 [monthly]
Completed
-
Oct 2025 — Nov 2025 [monthly]
Completed
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
▶ Show 9 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Dec 2021 — Dec 2022 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Sep 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Sep 2020 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Aalen, Germany , Aarbergen, Germany , Ahaus, Germany , Ahaus-Alstaette, Germany , Ahrensburg, Germany , Aichtal, Germany , Albersloh, Germany , Albstadt, Germany , Albstadt-Ebingen, Germany and 880 more locations